Pasithea Therapeutics (KTTA) Stock Price, News & Analysis

Company Overview

Pasithea Therapeutics, Inc. (NASDAQ: KTTA) is a clinical‐stage biopharmaceutical company focused on the discovery, development and eventual commercialization of engineered antibody therapeutics for immunological diseases. Leveraging a proprietary discovery engine that integrates advanced computational biology, high-throughput screening and structural analysis, the company aims to identify and generate novel therapeutic molecules that modulate key immune pathways.

The company’s pipeline consists of multiple preclinical and early clinical candidates targeting autoimmune and inflammatory disorders. Pasithea’s research approach centers on human-derived antibodies with tailored specificity and functionality, addressing areas of high unmet need such as severe chronic inflammatory conditions. By applying its platform to a range of targets, Pasithea seeks to advance innovative therapies toward regulatory milestones and strategic partnerships.

Headquartered in Seattle, Washington, Pasithea Therapeutics maintains research and development operations in the Pacific Northwest, with teams dedicated to antibody engineering, translational science and regulatory strategy. The company is led by a management team with experience in biotechnology innovation, clinical development and commercialization, supported by a board of directors and scientific advisors drawn from leading academic and industry institutions. Pasithea continues to explore collaborations with academic centers and pharmaceutical partners to accelerate its therapeutic programs.

Key Stats

• Today's Range: $0.83 to $0.90
• 50-Day Range: $0.67 to $0.88
• 52-Week Range: $0.28 to $3.79
• Volume: 453,380 shs
• Average Volume: 353,827 shs
• Market Capitalization: $21.20 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $3.00
• Consensus Rating: Reduce

Pasithea Therapeutics Stock Analysis - MarketRank™

Pasithea Therapeutics scored higher than 45% of companies evaluated by MarketBeat, and ranked 549th out of 856 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.4 / 5
• Analyst Rating: Reduce

Consensus Rating

Pasithea Therapeutics has received a consensus rating of Reduce. The company's average rating score is 1.67, and is based on no strong buy ratings, 1 buy rating, no hold ratings, and 2 sell ratings.

Upside Potential

Pasithea Therapeutics has a consensus price target of $3.00, representing about 252.9% upside from its current price of $0.85.

Amount of Analyst Coverage

Pasithea Therapeutics has only been the subject of 3 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Decreasing

Earnings Growth

Earnings for Pasithea Therapeutics are expected to decrease in the coming year, from ($1.86) to ($2.10) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Pasithea Therapeutics is -0.24, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Pasithea Therapeutics is -0.24, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Pasithea Therapeutics has a P/B Ratio of 0.36. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

Short Interest

• Score: 3.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

0.93% of the float of Pasithea Therapeutics has been sold short.

Short Interest Ratio / Days to Cover

Pasithea Therapeutics has a short interest ratio ("days to cover") of 0.17, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Pasithea Therapeutics has recently increased by 86.12%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Pasithea Therapeutics does not currently pay a dividend.

Dividend Growth

Pasithea Therapeutics does not have a long track record of dividend growth.

News and Social Media

• Score: 2.3 / 5
• News Sentiment: 0.69

News Sentiment

Pasithea Therapeutics has a news sentiment score of 0.69. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.

News Coverage This Week

MarketBeat has tracked 2 news articles for Pasithea Therapeutics this week, compared to 2 articles on an average week.

MarketBeat Follows

2 people have added Pasithea Therapeutics to their MarketBeat watchlist in the last 30 days.

Company Ownership

• Score: 0.4 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Pasithea Therapeutics insiders have not sold or bought any company stock.

Percentage Held by Insiders

2.00% of the stock of Pasithea Therapeutics is held by insiders.

Percentage Held by Institutions

23.92% of the stock of Pasithea Therapeutics is held by institutions.

KTTA Stock Analysis - Frequently Asked Questions

How have KTTA shares performed this year?

Pasithea Therapeutics' stock was trading at $1.29 at the beginning of 2026. Since then, KTTA stock has decreased by 34.1% and is now trading at $0.85.

How were Pasithea Therapeutics' earnings last quarter?

Pasithea Therapeutics Corp. (NASDAQ:KTTA) issued its quarterly earnings results on Monday, March, 30th. The company reported ($0.89) EPS for the quarter, missing analysts' consensus estimates of ($0.18) by $0.71.

When did Pasithea Therapeutics' stock split?

Pasithea Therapeutics shares reverse split on Tuesday, January 2nd 2024.The 1-20 reverse split was announced on Tuesday, January 2nd 2024. The number of shares owned by shareholders was adjusted after the market closes on Tuesday, January 2nd 2024. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split.

When did Pasithea Therapeutics IPO?

Pasithea Therapeutics (KTTA) raised $17 million in an IPO on Wednesday, September 15th 2021. The company issued 2,898,551 shares at $5.00-$7.00 per share.

Who are Pasithea Therapeutics' major shareholders?

Pasithea Therapeutics' top institutional shareholders include AdvisorShares Investments LLC (1.35%). Insiders that own company stock include Tiago Marques and Simon Dumesnil.
View institutional ownership trends.

How do I buy shares of Pasithea Therapeutics?

Shares of KTTA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Pasithea Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Pasithea Therapeutics investors own include Biofrontera (BFRI), Meta Platforms (META), Plug Power (PLUG), QuantumScape (QS), Airbnb (ABNB), Advanced Micro Devices (AMD) and Ginkgo Bioworks (DNA).

Company Calendar

• Last Earnings: 3/30/2026
• Today: 5/05/2026
• Next Earnings (Estimated): 5/21/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:KTTA
• CIK: 1841330
• Web: www.pasithea.com
• Phone: 702-514-4174
• Fax: N/A
• Employees: 3
• Year Founded: 2020

Price Target and Rating

• Average Price Target for Pasithea Therapeutics: $3.00
• High Price Target: $3.00
• Low Price Target: $3.00
• Potential Upside/Downside: +252.9%
• Consensus Rating: Reduce
• Rating Score (0-4): 1.67
• Research Coverage: 3 Analysts

Profitability

• EPS (Trailing Twelve Months): ($3.57)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$20.43 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -85.48%
• Return on Assets: -77.42%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 11.35
• Quick Ratio: 11.35

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $2.39 per share
• Price / Book: 0.36

Miscellaneous

• Outstanding Shares: 24,940,000
• Free Float: 24,441,000
• Market Cap: $21.20 million
• Optionable: Not Optionable
• Beta: 0.22